Ocutrx Technologies, Inc. 2022 (EDE)

1

3D Visualization Ecosystem

The future of healthcare, at the intersection of Life Sciences, Tech, AR, & AI.

© 2022

2 The contents of this slide deck does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Ocutrx Technologies, Inc. or any other third party regardless of whether such security, product or service is referenced in this on-line magazine. Before making an investment an prospective investor must first read the Ocutrx Round B Private Placement Memorandum, and any further information the investor needs. Furthermore, nothing in this on-line magazine slide deck is intended to provide tax, legal, or investment advice and nothing should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction. Neither Ocutrx Technologies, Inc. nor its advisors represent that the securities, products, or services discussed in this on-line magazine slide deck are suitable for any particular investor. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your business advisor, attorney, or tax and accounting advisor regarding your specific business, legal or tax situation.

Copyright 2022 Ocutrx Technologies, Inc. All rights reserved.

3

Ocutrx’s 3D Visualization Ecosystem Surgery & Clinician

ORLenz AR for Surgeons

StereoLenz 8K 3D Monitor

CamTrx Digital Microscope

Patient & Enterprise

OR-Bot Surgery Visualization Theatre

Oculenz AR for AMD

Oculenz RMP for Telehealth

Pioneering 3D visualization for patients, surgeons, and more.

Oculenz EPIC Enterprise & Military

4

Our Markets Advanced Macular Degeneration (AMD)

$30B

Medical Visualization

Augmented Reality (AR/XR)

4

$70B

$340B by 2024

Anticipated to register a CAGR of 43.8% from 2021 to 2028

Grand View Research, Inc.

4

OcuLenz® AR Headset for Advanced Macular Degeneration (AMD) First product to market

6

What’s the problem?

Age-Related Macular Degeneration* (AMD) is a debilitating central vision disease effecting 30M worldwide.

*Also referred to as the “Alzheimer’s of the eyes”

7

Imagine spending a lifetime planning your golden years, and then not being able to see the moments you’ve worked so hard to savor.

NORMAL VISION

EARLY AMD

INTERMEDIATE AMD

ADVANCED AMD

AMD robs millions of their Macu sight and everything that makes life worth living.

8

Current AMD correction • Heavy or tethered • Indoor use only • No peripheral vision • Cannot walk with device • Device only magnifies • Does not restoreM quality of life acu • Does not relinquish caretaker obligations

9

Our solution…

Oculenz AMD™ AR Headset • Lightest weight and tetherless • Indoor & outdoor use • Widest field-of-view • Patented AR headset • Restores user’s independence Macu • Relinquishes caretaker obligations

Commercialization scheduled 2022

FDA 510(k) exempt

10

How does OcuLenz work?

STEP 1 STEP 2 Patented Visual Field Test Patient puts on Oculenz headset.

Software finds patient’s blind-spot (5 minutes per eye).

Patented Video Pixel Manipulation Blind-spot shape & size are stored in the headset. Software moves images and text outside of patient’s blind-spot.

STEP 3

STEP 4 Patented SaaS model with recurring revenue Blind-spot size & shape are sent to user’s Ophthalmologist via HIPPA-secured cloud.

Allows physician to monitor disease progression remotely.

Patented visual correction Patient can see as if they did not have blind-spot.

Can be worn all day for all tasks.

11

AMD without OcuLenz:

AMD with OcuLenz:

What the user sees/perceives:

12

Click to watch 1 minute video of our Patient Trial

Video opens in a new window. If video does not play automatically, please click the screen.

13

Click to watch 30 second video of OcuLenz user’s exit interview

OR-Bot® Surgical Visualization Theatre Second product to market

15

CEO Michael Freeman spoke at lowvision conferences around the world and told Ophthalmic surgeons about an AR solution for their patients, and the surgeons said, “We need better visualization, too!”

STORY OF TRANSITION

16

Problems in the OR Poor Ergonomics

• Current surgery systems force surgeons to strain back, neck, and arms during operations

Alcon’s Ngenuity

Space Constrains

• Current surgery systems require SOM and digital camera to be directly over the patient, which limit surgeon’s agility

Inferior Resolution

• Current surgery systems have limited resolution at 1080P • Current surgery systems do not have true 4K resolution • 3D glasses don’t work - block 50% of light and obscure surgeon’s vision Intuitive Surgical da Vinci

17

Click to watch video about problems in the OR

18

Our solution…

OR-Bot™

Surgical Visualization Theatre 3 unique visualization methods: ORLenz™ 4K XR Headset • Surgical video feed in 3D with 6DoF StereoLenz™ 8K 3D “glasses free” monitor • Eliminates the need for 3D glasses MiniLenz™ 4K VR Digital Microscope • Cobotic arm adjusts to surgeon’s posture

Click to watch OR-Bot video

20 CamTrx ™

Digital Microscope • Sends 3D surgery feed to the ORBot’s three visualization methods

FDA 510(k) exempt

• 12K Resolution • Color spectrum of 69 billion colors • Can resolve down to 5 microns

Optical Magnification

.8x - 4.8x

Digital Magnification

20x – 180x (4K) 60x - 360x (Full HD)

OR-Bot Visualization Source

21

ORLenz™ AR/XR

Surgery Visualization headset The OR-Bot displays surgery video feed from Camtrx Microscope to ORLenz AR/XR headset.

Resolution

5K

Weight

415 grams

Field-of-view

60º x 40º

Wireless

(2560 x 1440 per eye)

OR-Bot Visualization Option #1

22

Click to watch features video of ORLenz

Example of Medtiles™ Information Overlay

23

StereoLenz™ 8K 3D “Glasses-Free” Monitor

The OR-Bot displays surgery video feed from Camtrx Microscope to the StereoLenz, enabling user to see in 3D without needing to wear 3D glasses.

Resolution

8K (4K per eye)

Megapixels

13.6

FDA 510(k) exempt

Headtracking Eyetracking

OR-Bot Visualization Option #2

24

MiniLenz™ 4K VR Oculars The OR-Bot displays surgery video feed from Camtrx Microscope to MiniLenz VR Oculars.

FDA 510(k) exempt

• 4K resolution • Attached to ‘cobotic arm’ and adjusts to surgeon’s posture • Eliminates standard optical scope, reduces space constraints in OR Resolution

5K

FOV

60º x 40º

OR-Bot Visualization Option #3

Future Products

Ocutrx’s AI engine Neural Datrx™ • Ocutrx AI Supports new models of care • Helps Med Students learn in 3D instead of 2D • Platform for Tele-health, Tele-surgery Assist & Tele-Diagnosis • Predictive Outcomes • Provides “Most Selected” Elective Surgery Choices ”MR. AI for Ophthalmology” Dr. Daniel Ting, Ocutrx Medical Advisor

27

Oculenz™ RMP Remote Medical Presence for Telemedicine • Real-time video chat with a physician • Video above 4K resolution • HIPAA-secured transmission of patient vitals: • respiratory effort • respiratory rate • visual field tests • blood pressure • pulse oximeter • eye-tracking • temperature • heart rate • weight • EKG • OCT 2020 First Families COVID Response Act mandates Medicare reimbursement

28

QA-Bot™

Quality Assurance Remote Circuit Board Examination • Gives circuit board companies the ability to remotely inspect • Can inspect 5 most common PCB repairs: • Physical damage • Component failure • Trace damage • Boor design • Power failure • Reduces waste • Saves time

29

Scopetrx™ 3D Swivel Camera Laparoscopic Instrument

• Wireless Real-time video to ORLenz or OR-Bot • Video 4K resolution • 360º x 270º Swivel Camera • Dual lighting around camera and added light tool • Surgeon can see both inside and outside of patient at the same time • Digital camera/tool depth readout • Trochar blades close and retract • Trochar barrel only 8mm so no suturing

Developed in conjunction with Dr. David L. Street, M.D, Vascular Surgeon who developed many laparoscopic techniques in the early 1980s

Offering & Financials

S p e c i a l O ff e r i n g Round B

$25M @ $3.00 per share

Special Offer

$3.00per share $2.50 per share

plus

warrant shares

30% warrant shares $2.00 per share Three-year option

32

O c u t r x ’s Ca p Ta b l e

Total Raise $14M

Other

80%

Doctors & Surgeons

Founders, Employees, Advisors

33

Oc utr x Va l ua tio n

Round B1 Round B1

Round A

Share Price: $1.25 Shares Issued: 25,540,129 Valuation: $31.9M

Share Price: $2.25 Shares Issued: 851,005 Valuation: $65.8M

29, 536,999* (total paid shares) x (last round closed) = value *Includes warrants executed from previous rounds.

total shares sold

Share Price: $3.00 Shares Issued: 325,217 Round still in progress

34

Path to IPO

IPO Preparation for listing

Q4 2022 Oculenz AMD Revenue & Target Revenue

Q3 2022

Q2 2023

Team Ocutrx

Founders 36

Dr. Michael Freeman, JD CEO/CTO Mr. Mitch Freeman COO • • • • • •

Invented “streaming mobile video” Sold technology to Samsung Technology became foundation for IEEE 802.11(n) MIMO standards Today this technology is used when we send videos and use 4G 100+ combined patents Founded Ocutrx to correct father’s AMD

Brig. Gen. Richard Freeman

Michael Freeman, CEO/CTO

Mitchael Freeman, COO

37

Top Management

Kevin Griffin CPA Chief Financial Officer

Simon Prosser Global Director of Surgical Applications

John Bluher JD Director of Finance

Jim Gatzimas Chief Commercial Officer, Electronics

Engineering Team

Victoria McArtor MFA Chief Communications Officer

Marc Stenzel Director of Low Vision Sales

Jordan Boss Chief Product Engineer

David Kessler, PhD Chief Optical Engineer

Steven Von der Porten Senior Optical Engineer

Ben Rafiee Chief Mechanical Engineer

65+ Hardware and Software engineers in California, Oklahoma, Colorado, and Italy (contract workers) Linda Lam MD MBA

Chief Scientific & Strategy Officer

Montgomery Freeman Chief Marketing Officer

Mary Van Orman, JD Chief Compliance Officer

38

International Medical Advisory Board

Thomas Finley MD Linda Lam MD MBA Richard Lindstrom MD Cuong Vu MD Retina Surgeon Retina Surgeon Retina Surgeon Retina Surgeon Minnesota Eye Clinic Retina Grp of USC Tulsa, OK Wash.

Daniel Ting Retina Surgeon Singapore

Diane Whitaker OD Optometrist Duke

Sam Garg MD Ronald Krueger MD Refractive Surgeon Ophthalmologist UC Irvine Nebraska

Pat Yoshinaga OD Optometrist Ketchum University

Hugo Mercado MD Michael Albert MD Lars Freisberg MD Retina Surgeon Retina Surgeon Retina Surgeon Mexico City Univ. of Alabama Tulsa

International Surgical Steering Committee

Mark Blumenkranz MD Daniel Palanker MD Thomas Krummel MD Cardiothoracic Sgrn Retina Surgeon Retina Surgeon Stanford Stanford Stanford

Ernesto Bali MD Retina Surgeon Brussels

George Caputo MD Retina Surgeon Paris

David Street MD Vascular Surgeon Oregon

Kevin Turner MD James Rodgers MD Peter Odland MD OBGYN Neuro + Spine Surgeon Dermatologist Washington Tulsa Washington

Click advisor’s name for more information

Advisors

Dr. Frederic Moll, MD

Dr. Bill Link, PhD.

Dr. Mark Blumenkranz, MD

Mr. Vic Gundotra

Traction, Timing, & Value

41

Patents

12

US PATENTS

6 patents on AR hardware 6 patents on Optical Engine

116

PENDING

35 patent families

160+

EXPECTED

For micro-displays, applications, connectivity, & more.

42

Partnerships ATT data connection & cellular plans, US ORANGE data connection & cellular plans, EU/UK QUALCOMM XR-2 chipset • Ocutrx has reference designs for circuit boards • Ocutrx has coveted Tier 1 status with Qualcomm, putting Ocutrx on par with Samsung, Apple, M. Benz, Fiat-Chrysler KARTEN DESIGNS Medical Device Designs SONY camera & micro-display vendor HOGAN LOVELLS FDA & regulatory counsel STRADLING Law Firm Corporate counsel IEXCEL University of Nebraska Medical Center’s “Surgery Suite of the Future”

Tier 1 status

43 Ocutrx Product Timeline

Q3 2022

Q4 2022

Go to market (US)

Q2 2023

Alpha & Beta Testing

Final Commercialization

Alpha & Beta Testing

Clinical Assessment (US/UK/EU)

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Go to market (UK/EU)

FDA 510(k) exempt

Final Commercialization

OR-Bot

Q1 2023

CE Mark (UK/EU)

StereoLenz

Alpha & Beta Testing

Q2 2022

ORLenz

OcuLenz AMD

Q12022

CE Testing for UK/EU Go to market (US)

Go to market (UK/EU)

FDA 510(k) exempt

CE Testing for UK/EUX Go to market (US)

FDA + MDR Go to market (US)

Go to market (US/UK/EU)

Clinical Trials (FDA & CE)

Go to market (UK/EU)

Future Collaboration

• Google appreciates the humanitarian nature of the OcuLenz AMD software • Offered to alter Android Operating System to better serve OcuLenz programs • Asked Ocutrx engineers for wish list of features to be changed before our final go-to-market OcuLenz AMD headset

Mr. Clay Bavor

Google Vice President of Virtual & Augmented Reality

45

OR-Bot Potential Distribution Partners

…plus additional potential partners who wish to remain confidential under NDA.

46

OR-Bot and UNMC • OR-Bot will soon be on permanent display at UNMC’s iEXCEL Medical Training Center.

• Ocutrx will be part of Davis Global Center’s “Surgery Suite of the Future.”

• In collaboration with AT&T for 5G-MEC for 100x faster downloads of critical medical data.

Surgeons who play video games make 37% fewer errors & complete surgery 27% faster.*

*2021 PUB MED survey

Ocutrx’s AR/XR circuit board 47

Ocutrx has Tier 1 status w/ Qualcomm

with Qualcomm’s XR2 chipset • • • • • • • • • • • • • • • • •

4G/5G Cellphone enabled 5G (mm Wave and sub-6GHz bands) Wi-Fi enabled Bluetooth 5 and BTL enabled Enables 7 Cameras simultaneously 3D Audio in 3 Sound Options SLAM enabled Hand and Head Gesturing Eye and Gaze Tracking Siri enabled 3D enabled Voice UI and context awareness 6DOF tracking 5G -Multi-Access Edge Computing (MEC) Artificial Intelligence (AI) engine EVA (Engine for Visual Analytics) WiDtrx – Wireless internet as fast as wired

AT&T provides WiFi, 4G/5G/5G MEC

Competitive Comparisons

49

OcuLenz

Competitive Comparisons AMD correction in market OcuLenz

Resolution 2304 × 1440 (per eye) FOV

60°

NuEyez

eSight

Allows patient to see around blind spot

OxSight

1290 x 720

?

?

30°

?

?

NuEyez

Magnification only

See around Scotoma?

eSight

Magnification only

True AR AR Overlay Price

$6,000

$6,195

$9,995

$1,799

OxSight

Magnification only Handheld only

50

Competitive Comparisons AR and Surgical headsets in market

ORLenz

$65.7M Valuation “Ocutrx seems to be something that advanced hospitals interested in AR may wish to investigate.”

-Forbes

MAGIC LEAP $2B Valuation

“The Terrible View Through Diffraction Gratings.”

-Karl Guttag on Technology

HOLOLENS $1B Valuation

“HoloLens 2 is Likely Using Laser Beam Scanning Display: Bad Combined with Worse.”

-Karl Guttag on Technology

AUGMEDICS $61M Valuation

“Heavy with limited Field-of-View.”

- Dr. Linda Lam

BEYEONICS

$11M Valuation “Tethered and heavy with very dark lenses and limited Field-of-View.”

-Dr. Linda Lam

51

ORLenz

Competitive Comparisons

Highest resolution Highest FOV Lightest Weight

AR and Surgical headsets in market ORLenz

Resolution 2304 × 1440 (per eye) FOV

60°

HoloLens

Beyeonics

Augmedics

800 x 600

854 x 480

1280 x 720

52°

30°

50°

HoloLens

Poor resolution Narrow FOV Chromatic Aberration Heavy

Wireless True AR Weight

Beyeonics 375g

575g

700g

More like VR than AR Tethered Heaviest on market

725g

AR Overlay 5G enabled?

Augmedics Poor resolution Narrow FOV Heavy

52

What’s the competitor’s problem?

Example of Chromatic Aberration in HoloLens 2 caused by Waveguide.

Ocutrx’s CEO knew Waveguide would not be able to give patients, surgeons, or the military the image quality they needed, so they developed a Near-Eye PupilForming Catadioptric optical engine.

Ocutrx is the only AR company to pivot from Waveguide and patent their own optical engine.

https://kguttag.com/2019/12/18/hololens-2-not-a-pretty-picture

53

Optics Comparison

HoloLens 2

Ocutrx

54

Competitive Comparisons 3D monitors StereoLenz

Ocutrx

Artevo

Zeiss

Alcon

4K+

½ 4K

2K

Brightness

95%

50%

50%

Latency

20ms

80ms

80ms

Zoom

12x

6x

6x

Megapixels

13.6

4.2

2.1

Needs 3D Glasses?

No

Yes

Yes

$34,999

~$60,000

Look directly into monitor.

Can see in 3D without wearing 3D glasses.

Ngenuity

Resolution

Price

OCUTRX

~$50,000

ZEISS

Must turn head to see around microscope.

Must wear 3D glasses.

ALCON

Must rotate hip to see around microscope.

Must wear 3D glasses.

Our Plan for Vertical Integration

Ocutrx in contract to acquire circuit board and final assembly manufacturing facility (“Target”) •

Target is FDA ISO 13485 qualified/certified, giving Ocutrx FDA compliance

•

Ocutrx has ability to expand Target’s circuit board sales by leveraging Tier-1 relationship with Qualcomm

•

Enables Ocutrx to repatriate supply chain to US; reduces domestic cost of Ocutrx products to approx. same cost as China

•

Plant brings DoD & Fortune 500 clientele to Ocutrx

57

A c q ui si ti o n Ti m e l i n e

Q4 ‘20

Target Valuation conducted by Deloitte

Q3 ‘21

Q1 ‘22

LOI signed Due Diligence begins

Due Diligence completed

Today

$7M debt financing secured $4M equity needed to close

July '22

Option to purchase Target ends

Target’s P&L 2017-2021 (actual) 2022 (confirmed POs)*

$11,646,138 $10,271,000 $7,927,557

$6,511,103 $4,887,260 $4,294,478

$6,119,607

$6,112,947

$6,371,373

$3,982,015 $2,529,088

2018

$3,771,132

$2,962,258 $1,807,950

$592,782 2017

$7,123,691

$7,728,868

2019

Gross Revenue

$1,010,074

2020

Total Expense

2021

EBITDA

2022

59

Ta rg e t Va l ua ti o n

2020 $13,829,000

2021 $18,768,000

Indicated Value of Equity Marketable, Control Basis

(Based on $10.2M Revenue Using Deloitte Model)

(Based on $7.509M Revenue)

Valuation Model 12/2020

60

C o n s o l i d a t e d Va l u a t i o n Current Valuations Pre-Acquisition

Expected Valuation Post Acquisition, Post Round B ($25M)

Target $18.7M*

Target $15.2M* *81% ownership

Ocutrx $65.8M

Ocutrx $111.9M*

*Deloitte, 2020

*4 AR & 5 surgery products

Combined

Target & Ocutrx $111.9M $127M

*Positive EBITDA 114 Patents pending

61

Amount to Close Acquisition

TARGET FEES

Contract Purchase Price $10,126,579 Est Excess Inventory Adj. $266,811 Closing Fees $125,000

OCUTRX FEES

Ocutrx Fees

Placement Fees Legal & Closing Fees Integration & Operations

Total:

$811,610 $100,000 $500,000

$12,000,000

Target Fees

THANK YOU

For more information & instructions on how to participate please contact: Victoria McArtor Victoria.McArtor@Ocutrxtech.com (918) 697-0494 Michael Freeman Michael.Freeman@Ocutrxtech.com (949) 630-8607

63

Fo r w a rd l o o k i n g s t a t e m e n t s disclaimer Certain statements that Ocutrx Technologies, Inc. (the “Company”) has included in this PowerPoint may constitute "forward-looking statements" and are subject to a number of significant risks, uncertainties and estimations. Any such forward-looking statements contained herein should not be relied upon as predictions of future events. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," “can,” "may," "will," "should," "approximately," "intends," "plans," "estimates," or "anticipates" or the negative thereof or other variations thereof or comparable terminology, or by discussions of strategy, plans or intentions. Such forward-looking statements are subject to numerous risks and are necessarily dependent on assumptions, data or methods that may be incorrect or imprecise and may not be realized. Thus, the matters discussed below and elsewhere could cause actual results, returns and other matters to differ materially from those in such forward-looking statements. As a result of the foregoing, no assurances can be or are given as to future results of operations or financial condition of the Company or its Subsidiaries. This PowerPoint is only available to persons and/or entities who are Accredited and Qualified Investors, and who agree to keep all financial information confidential and not disclose to 3rd parties. Further, additional information, interviews, and a review of the Company’s Private Placement Memorandum is required before making any investment decision.

Other appropriate information may be reasonably requested from representatives, advisors, attorneys and/or accountants of the Company. Except as otherwise stated herein, all rights and copyrights to the materials, analysis, projects and plans are reserved and claimed by the Company. No portion of these materials may be copied, or disclosed to anyone other than the recipient nor reproduced without the express written permission of Ocutrx Technologies, Inc. Copyright 2021 Ocutrx Technologies, Inc. All rights reserved.

64 Disclaimers This Presentation (the “Presentation”) contains sensitive business and financial information. It is being delivered on behalf of the Company by Company Agents. The sole purpose of this Presentation is to assist the recipient in deciding whether to proceed with a further inquiry of the Company. This Presentation does not purport to be all-inclusive or to necessarily contain all the information that a prospective investor may desire in evaluating a possible business transaction with the Company. Before making an investment decision a prospective investor must read the Ocutrx Round B Private Placement Memorandum By accepting this Presentation, the recipient agrees to keep confidential the information contained herein or made available in connection with any further inquiry of the Company. This Presentation may not be photocopied, reproduced or distributed to others at any time without the prior written consent of Ocutrx Technologies, Inc. Upon request, the recipient will promptly return all materials received from the Company or BSL (including this Presentation) without retaining any copies thereof, all in accordance with the Confidentiality Agreement.

This Presentation has been prepared for informational purposes relating to this transaction only and upon the express understanding that it will be used only for the purposes set forth above. Neither the Company nor its Agents makes any express or implied representation or warranty as to the accuracy or completeness of the information contained herein or made available in connection with any further investigation of the Company. The Company expressly disclaims any and all liability which may be based on such information, errors therein or omissions there from. The recipient shall be entitled to rely solely on the representations and warranties made to it in any definitive agreement and the due diligence that recipient conducts.

In furnishing this Presentation, the Company undertakes no obligation to provide the recipient with access to any additional information. This Presentation shall neither be deemed an indication of the state of affairs of the Company nor constitute an indication that there has not been any change in the Company or affairs of the Company since the date hereof. This Presentation does not constitute an offer to sell or solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation in such jurisdiction.

Investments in private placements may be illiquid, highly speculative and you may lose your entire investment.

This Presentation includes certain statements, estimates and projections with respect to the anticipated future performance of the Company. Such statements, estimates and projections are based on significant assumptions and subjective judgment concerning anticipated results. These assumptions and judgments are inherently subject to risks, variability and contingencies, many of which are beyond the Company’s control. These assumptions and judgments may or may not prove to be correct and there can be no assurance that any projected results are obtainable or will be realized. Actual results likely will vary from those projected, and such variations may be material. In addition, this Presentation does not describe certain risks associated with the Company’s business. Ocutrx Technologies, Inc. © 2022 All rights reserved.